Headlines

Vertex to pay CRISPR $100m to use gene editing tech for diabetes therapy

Vertex will pay CRISPR Therapeutics $100m up-front for non-exclusive rights to its technology with the goal of developing a certain type of therapy for diabetes.

BrainStorm secures FDA advisory meeting for ALS drug

BrainStorm Cell Therapeutics reports that the FDA is to hold an advisory committee meeting to discuss the company’s BLA for NurOwn, a personalized stem cell treatment targeted at ALS.

Content provided by Thermo Fisher Scientific - Biosciences

Is GMP grade good enough? What mRNA manufacturers need to know when buying raw materials

Starting with the end in mind when choosing mRNA raw materials help mitigate costly risks. Seeking quality attributes that go beyond GMP grade is key.

US government announces ambitions for biomanufacturing

The White House releases a report detailing how it will harness biotechnology and biomanufacturing to address numerous societal challenges, including human health.